Are all GLP-1 products FDA-approved for weight loss?

No. Approval depends on the exact brand, dose, and indication. Diabetes and obesity labels are not interchangeable. NIDDK lists several FDA-approved chronic weight-management medicines, including incretin and non-incretin options. A clinic vial, telehealth “generic,” or compounded product is not the approved drug. Ask for the product name as it appears on the FDA label.

Is compounded semaglutide or tirzepatide the same as the brand?

No. FDA states compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. The agency has reported dosing errors, hospitalization, salt forms that differ from approved products, and illegal sameness claims. Compounding is for a specific medical need that an available approved drug cannot meet—not a cheaper look-alike sold as Wegovy or Zepbound.

Will I lose muscle on a GLP-1 medicine?

Some lean mass usually falls when total weight falls. That is why monitoring includes protein intake and resistance training, not scale weight alone. ACSM still recommends muscle-strengthening at least twice weekly for adults when safe. Rapid, very-low-intake loss raises the chance that too much of the change is lean tissue. Report weakness, falls, or a disappearing training load.

Do I stay on medication forever?

Obesity is often a long-term disease. Stopping an effective medicine commonly leads to regain, so duration should be discussed before the first dose. Cost, coverage, side effects, and pregnancy plans all affect that decision. NIDDK advises against using these medicines only to change appearance. If access ends, have a nutrition and activity maintenance plan ready.

Weight Management

GLP-1 and Other Anti-Obesity Medications

GLP-1 and other anti-obesity drugs need an FDA-approved product, monitoring, and a protein-and-strength plan. Compounded copies are not the same.

Overview

Anti-obesity medication management is licensed prescribing and follow-up for FDA-approved chronic weight-management drugs—not a cash vial and a scale photo. NIDDK lists incretin options such as GLP-1 receptor agonists and dual GIP/GLP-1 therapy, plus non-incretin medicines including phentermine/topiramate extended-release, naltrexone/bupropion, and orlistat. Product labels differ. Selection depends on cardiovascular disease, diabetes, blood pressure, seizure or eating-disorder history, pregnancy plans, gallbladder or pancreatitis history, interactions, and cost. NIDDK is explicit: do not take these medicines only to change appearance. Semaglutide and tirzepatide products used for diabetes are not automatically the obesity dose or brand.

FDA-approved products have been reviewed for safety, effectiveness, and quality. Compounded copies have not. FDA consumer pages warn that unapproved GLP-1 drugs—including some compounded semaglutide and tirzepatide—are not the same as Wegovy, Ozempic, Mounjaro, or Zepbound. The agency has reported dosing errors that required hospitalization, concentrations that confuse milligrams with milliliters, salt forms that are not the approved active ingredient, and fraudulent labels. Compounding may be considered only when an available approved drug cannot meet a specific medical need. “Cheaper” and “same peptide” are not that need. After shortage resolutions, mass-market compounded look-alikes have faced increasing FDA enforcement.

Monitoring is part of the medicine. Doses escalate slowly. Follow-up should track nausea, vomiting, constipation, hydration, gallbladder or pancreatitis symptoms, mood when relevant, and other glucose-lowering drugs that may need reduction. Because appetite and intake fall, the visit should also set protein targets and resistance training so a larger share of loss is fat rather than muscle. ACSM adult guidelines still include muscle-strengthening on two or more days weekly when safe. Stopping often leads to regain; discuss duration and a taper or maintenance plan before the first injection.

This service does not replace nutrition care, sleep-apnea treatment, or indicated surgery. A telehealth mill that ships an unlabeled syringe without a contraindication review is not medication management. Ask for the exact FDA-approved name, the indication on the label, and who you call after hours for severe abdominal pain or repeated vomiting.

Prefer the FDA-approved product that matches your indication.
Pair every dose increase with protein, fluid, and strength check-ins.

Benefits

Can produce clinically meaningful weight loss and risk-factor change when the labeled product fits

Compares incretin and non-incretin options by contraindication and comorbidity

Distinguishes FDA-approved drugs from compounded or unapproved look-alikes

Monitors gastrointestinal, gallbladder, mood, and hypoglycemia risks during titration

Protects muscle with protein intake and resistance-training plans

Sets a maintenance or discontinuation plan before the first dose

Preparation

Bring every medicine and supplement, insurance formulary or prior-authorization papers, history of pancreatitis, gallbladder disease, or severe reflux, mood or eating-disorder history, and pregnancy plans. Write whether you were offered a compounded vial and the product name on any current pen. Note baseline strength or activity so muscle loss can be watched.

Recovery & Aftercare

There is no procedure downtime. Nausea, constipation, diarrhea, or low intake are common during titration and often ease if the dose is held or slowed. Keep fluids and protein up. Resume usual activity unless dizziness or dehydration appears. Call promptly for severe persistent abdominal pain, repeated vomiting, signs of dehydration, allergic reaction, pregnancy, or a sharp mood change.

Risks & Considerations

Risks vary by drug and include gastrointestinal symptoms, gallbladder disease, pancreatitis, dehydration, hypoglycemia when insulin or sulfonylureas are not adjusted, and rare but serious mood changes. GLP-1 labels carry warnings about medullary thyroid cancer history and MEN2. Compounded products add dosing-error, contamination, and unknown-potency risk. Fetal exposure should be avoided; use contraception as labeled. Do not combine unapproved peptides with a prescription incretin.

GLP-1 and Other Anti-Obesity Medications

Overview

Benefits

The Procedure

Confirm indication and contraindications

Choose the exact FDA-approved product

Titrate and teach use

Monitor nutrition and muscle

Reassess benefit, access, and duration

Preparation

Recovery & Aftercare

Risks & Considerations

Frequently Asked Questions

References

Guides

For Providers

Company

Ideal Candidates

Looking for Weight Management?

Related Treatment Guides